NCT05745428

Brief Summary

Aortic dissection (AD) is a clinical condition belonging to the broader spectrum of Acute Aortic Syndromes, with high morbidity and mortality and characterised by the sudden formation of a breach within the tonaca intima of the aortic wall, from which the so-called false lumen originates.The most common risk factor for AD is hypertension, present in more than 70% of. Imaging, biomarkers and genetic predisposition are critical in confirming a suspected diagnosis and in determining the appropriate intervention for each patient. Specific features influencing management decisions are the presence of rupture, extent of dissection, origin of true or false lumen vessels and signs of organ ischaemia.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Apr 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 10, 2022

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 7, 2022

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

February 15, 2023

Completed
12 days until next milestone

First Posted

Study publicly available on registry

February 27, 2023

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

April 16, 2024

Completed
Last Updated

March 1, 2023

Status Verified

February 1, 2023

Enrollment Period

8 months

First QC Date

February 15, 2023

Last Update Submit

February 27, 2023

Conditions

Keywords

hypertensionvasospasm

Outcome Measures

Primary Outcomes (3)

  • Evaluation of gene expression

    Evaluation of gene expression (by RT-qPCR),the analysis of circulating biomarkers smMYO11 (Human Myosin Heavy Chain 11, SmoothMuscle (MYH11) ELISA Kit, My Biosource), Calponin (Human Calponin-1 ELISA Kit, My Biosource) and MMP-9 (Human MMP-9 Quantikine ELISA Kit, R\&D System ) will be performed by enzyme immunoassay on suitably preserved serum from AD and CTRL partecipants, in accordance with the manufacturer's instructions.

    1 year

  • Evaluation of transcriptomics

    This study will be perfomed by single-cell analysis with enzyme immunoassay thanks to the peripheral blood sample that was taken from the participant at the time of enrollment

    1 year

  • Evaluation of protein

    This evaluation immunoenzymatic analyses, it's important to analyze altered biomarkers following fluid dynamic alterations applied by controlled mechanical stress to a model of primary cultures of aortic endothelial cells (HAOEC) and peripheral mononuclear cells (PBMC) isolated from enrolled subjects.

    1 year

Secondary Outcomes (1)

  • Assessment of correlation between circulating biomarkers

    1 year

Study Arms (2)

First group with aortic dissection

19 patients admitted to our Department of Cardiovascular Sciences with a radiological diagnosis of AD within 14 days of the onset of symptoms

Other: molecular and cellular analyses

Control Group

19 healthy outpatient or inpatient controls at our Department with another diagnosis and no evidence of AD, matched for demographic and clinical characteristics.

Other: molecular and cellular analyses

Interventions

sample blood

Also known as: Peripheral whole blood collection and isolation of mononuclear cells
Control GroupFirst group with aortic dissection

Eligibility Criteria

Age40 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The participants in this study present aortic dissection in its acute form (\< 14 days) leading to short-term complications such as aortic rupture and visceral malperfusion, while the subacute (15-90 days) and chronic (\> 90 days) forms lead to a process of aortic remodelling characterised by fibrinolysis and extracellular matrix (ECM) proteolysis, the latter being potential causes, in the long term, of gradual aortic dilatation with aneurysmal degeneration.

You may qualify if:

  • partecipants admitted to our Department of Cardiovascular Sciences with a radiological diagnosis of AD within 14 days of the onset of symptoms;
  • healthy outpatient or inpatient controls at our Department with another diagnosis and no evidence of AD, matched for demographic and clinical characteristics

You may not qualify if:

  • evidence of inflammatory diseases, infectious diseases, neoplasms, immunological or haematological disorders;
  • treatment with anti-inflammatory drugs with the exception of low-dose aspirin (75-160 mg);
  • age \> 85 years;
  • advanced chronic kidney disease with glomerular filtration rate (eGFR) estimated by MDRD equation \<30 ml/min./1.73 m2; 5) pregnancy;
  • dissection with traumatic aetiology;
  • failure to sign informed consent;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Roma, 00168, Italy

Location

Biospecimen

Retention: SAMPLES WITH DNA

circulating biomarker analysis, aortic endothelial cell culture, peripheral whole blood collection and isolation of mononuclear cells

MeSH Terms

Conditions

Aortic DissectionHypertension

Condition Hierarchy (Ancestors)

Dissection, Blood VesselAneurysmVascular DiseasesCardiovascular DiseasesAcute Aortic SyndromeAortic Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

February 15, 2023

First Posted

February 27, 2023

Study Start

April 10, 2022

Primary Completion

December 7, 2022

Study Completion

April 16, 2024

Last Updated

March 1, 2023

Record last verified: 2023-02

Locations